Finance

Lists
GPCR:NASDAQ
Structure Therapeutics Inc
$36.81
+5.17%
(+1.81) 1D
$36.80
-0.03% (-0.010)
After hours
Closed: Sep 21, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GPCR...
Open
$35.34
High
$36.99
Low
$35.00
Mkt. cap
2.62B
Avg. vol.
969.37K
Volume
1.02M
52-wk high
$94.90
52-wk low
$23.59
EPS
-$3.11
Beta
-1.53
Shares outstanding
71.31M
No. of employees
281
Open
$35.34
High
$36.99
Low
$35.00
Mkt. cap
2.62B
Avg. vol.
969.37K
Volume
1.02M
52-wk high
$94.90
52-wk low
$23.59
EPS
-$3.11
Beta
-1.53
Shares outstanding
71.31M
No. of employees
281
News stories
From web sources and news partners
About Structure Therapeutics Inc
CEO-
Employees281
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Analyst ratings
Based on 14 analysts giving stock ratings to GPCR in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for GPCR in the last 3 months.
Highest
Current $36.81
$145.00 (+293.91%)
Average
$108.46 (+194.65%)
Lowest
$70.00 (+90.17%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Nash
Canaccord Genuity
Buy
Maintained
$111.00
+201.5%
09/09/2026
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$70.00
+90.2%
09/09/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$104.00
+182.5%
09/08/2026
Roger Song
Jefferies
Buy
Maintained
$125.00
+239.6%
09/08/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/08/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$99.00
+168.9%
09/08/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$100.00
+171.7%
08/17/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$126.00
+242.3%
08/10/2026
Samantha Semenkow
Citi
Buy
Maintained
$97.00
+163.5%
08/10/2026
Unknown Analyst
Jefferies
Buy
Maintained
$125.00
+239.6%
08/07/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$90.00
+144.5%
08/07/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+152.6%
08/07/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$145.00
+293.9%
08/06/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$110.00
+198.8%
08/07/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$140.00
+280.3%
08/07/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
$101.00
+174.4%
06/07/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$140.00
+280.3%
05/07/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$101.00
+174.4%
03/16/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
58.99M
68.69M
66.51M
100.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.80M
17.57M
22.87M
18.57M
Operating expense
73.79M
-13.74M
89.38M
118.63M
Total operating expenses
73.79M
-13.74M
89.38M
118.63M
Operating income
-73.79M
13.74M
-89.38M
-118.63M
Other non operating income
-
-
-
-
EBT including unusual items
-65.60M
33.17M
-75.78M
-105.92M
EBT excluding unusual items
-65.60M
35.75M
-75.78M
-105.92M
Income tax expense
108.00K
170.00K
190.00K
234.00K
Effective tax rate
-0.16%
0.51%
-0.25%
-0.22%
Other operating expenses
-
-100.00M
-
-
Net income
-65.71M
33.00M
-75.97M
-106.16M
Net profit margin
-
-
-
-
Earnings per share
-0.37
-0.46
-0.35
-0.49
Interest and investment income
8.18M
22.01M
13.60M
12.70M
Interest expense
-
-
-
-
Net interest expenses
8.18M
22.01M
13.60M
12.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-73.41M
14.47M
-88.79M
-118.06M
Gain or loss from assets sale
-
-10.25M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps